Evidence map›Paper›PMID 36910440›Full record

ArticleNorthern clinics of Istanbul2023

The results of following type 2 diabetes patients with mobile health services during the COVID-19 pandemic.

Kubra Gizem Nacak, Sema Ucak Basat, Mehmet Tayfur, Betul Ayaz, Ozge Siyer, Esra Bora, Zeynep Pelin Polat

Abstract read
In one paragraph

Article in Northern clinics of Istanbul, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kubra Gizem NacakDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Sema Ucak BasatDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Mehmet TayfurDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Betul AyazDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Ozge SiyerDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Esra BoraDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.
Zeynep Pelin PolatDepartment of Internal Medicine, Health Sciences University Umraniye Training and Research Hospital, Istanbul, Turkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study is to determine the level of compliance with treatment and achieving metabolic goals in type 2 diabetes mellitus (T2DM) patients who are remotely monitored with mobile health (mHealth) technologies during the pandemic.

methodsA total number of 86 patients were included in the study. Data from two periods were used: from 1 month before the date when the first COVID-19 case in Turkiye was reported on March 11, 2020 (Febraury 10, 2020-March 31, 2020) and from the pandemic was severe between April 01, 2020 and May 31, 2020. Participants' mean blood glucose, step count, blood pressure, body weight, and diet compliance levels were evaluated.

resultsWhen the blood sugar, blood pressure, and weight averages of the patients were compared between the pre-pandemic period and the pandemic months separately, no significant difference was observed. However, it was observed that the number of steps decreased significantly compared to the period before the pandemic (p<0.05). It was determined that 88% of the participants were able to access health services without applying to the hospital.

conclusionIn this study, we showed that patients with T2DM who were followed up with mHealth technologies provided the necessary metabolic control and compliance with the treatment during the pandemic.

Indexed as

COVID-19 pandemicdiabetes mellitusmobile health technologies

Identifiers

PMID36910440
PMCPMC9996655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.